Ella Hohmann, MS

SNAP participation was linked to a smaller colorectal cancer screening gap among food-insecure US adults, ananalysis of 251,000 found.

Alexander Spira, MD, PhD, FACP, FASCO, explains why sarcoma treatment lags behind other solid tumors and the access, subtype, and biomarker barriers.

FDA clears perioperative Keytruda + Padcev for all patients with muscle-invasive bladder cancer, establishing a new cisplatin-independent standard of care.

6 leading AI chatbots scored below 28% on a colorectal cancer knowledge test when barred from reasoning, raising fresh safety concerns for clinical use.

The first half of 2026 saw the FDA approve 5 notable first-in-class therapies across obesity, AML, kidney disease, hearing loss, and bladder cancer.

Quest Diagnostics is integrating its Haystack MRD and genomic profiling tests into Flatiron's OncoEMR, starting with an AON community oncology pilot.

Vera's atacicept (Trutakna) wins FDA accelerated approval after a 46% proteinuria drop in the ORIGIN 3 trial.

A proposed 2027 CMS rule would cut 340B Drug Pricing Program payments to curb Medicare drug costs and shift savings to patients.

Sarcoma's rarity and molecular diversity complicate trial design. Alexander Spira, MD, PhD, FACP, FASCO discusses biomarker testing, NGS panels, and referral gaps.

OLC's second complete response letter reflects an unresolved third-party manufacturing inspection, not new efficacy or safety concerns from the FDA.

Breast density raises cancer risk and masks tumors on mammography. Danielle Holt, MD, MSS, explains why density alone shouldn't trigger more imaging.

The FDA approved sacituzumab govitecan-hziy alone or with pembrolizumab as first-line therapy for metastatic triple-negative breast cancer.

Boston specialists discussed CKM syndrome, UACR screening gaps, and GDMT sequencing at a population health roundtable.

Caregivers of patients with CKD report social withdrawal, strained relationships, and stigma, according to a new qualitative evidence synthesis.

FDA approves palbociclib (Ibrance) for HR+, HER2+ metastatic breast cancer maintenance, based on phase 3 PATINA data showing a 24% reduction in progression risk.

FDA approval of generic rifapentine introduces a new option for treating active tuberculosis and preventing progression of latent infection.

EXTEND trial data show nurse-delivered telehealth for type 2 diabetes missed its primary end point in fee-for-service care, raising questions about reimbursement.

Alexander Spira, MD, PhD, FACP, FASCO, on why sarcoma diagnosis is often delayed and how community-academic collaboration speeds treatment.

OPTIMA shows Prosigna guides chemo decisions in high‑risk HR+ early breast cancer, sparing two‑thirds without raising 5‑year recurrence risk.

ASCO: City of Hope investigator highlights mosunetuzumab plus polatuzumab vedotin ADC/bispecific combo boosting PFS in LBCL with manageable adverse events outpatient.

Alexander Spira, MD, PhD, discusses why sarcoma treatment lags other cancers, citing tumor heterogeneity and inconsistent immunotherapy response as barriers.

I-SPY 2.2 of rilvegostomig plus trastuzumab deruxtecan in breast cancer treatment cut chemo use while exposing access issues and disparities.

Nancy Lin, MD, explores MMAI validation needs, turnaround advantages, equity implications, and how payers should approach AI-based diagnostics.

Rilvegostomig plus T-DXd achieved 57% pCR in HR+/immune+ HER2-negative breast cancer in I-SPY 2.2, potentially enabling surgery without chemotherapy.

Nancy Lin, MD, explains how an AI model compares with genomic classifiers in HR+/HER2- early breast cancer, with implications for cost and access.

State data reveal 2026 ACA marketplace enrollment losses are accelerating post open enrollment, as cancellations surge and affordability pressures mount after tax credits expired.

Rural America has 44% fewer health care workers per capita than urban areas, with psychologists and physicians hit hardest.

PROTEUS results reshape high‑risk localized prostate cancer care, adding apalutamide plus androgen deprivation before surgery as a new option.

By controlling for ovarian suppression, OPTIMA shows Prosigna works equally well in pre and postmenopausal high-risk early breast cancer.

The next frontier, according to Igor Puzanov, MD, MSCI, FACP, includes improving immune toxicity recognition and long-term care.